Presbyopia: a new potential pharmacological treatment

Area of Science:

• Ophthalmology
• Pharmacology
• Neuroscience

Background:

• Presbyopia is the age-related loss of the eye's ability to focus on near objects, typically occurring after age 40.
• Accommodation, the process of focusing, involves the ciliary muscle, iris, lens, and convergence, regulated by the parasympathetic nervous system.
• Muscarinic receptors in the ciliary muscle and iris are key targets for controlling accommodation.

Purpose of the Study:

• To investigate a novel pharmacological approach for correcting accommodation in emmetropic presbyopic patients.
• To evaluate the efficacy of a combined cholinergic agent and NSAID treatment for restoring near vision.

Main Methods:

• A pharmacological treatment combining a cholinergic agent with non-steroidal anti-inflammatory drugs (NSAIDs) was formulated.
• The study focused on emmetropic presbyopic patients, assessing changes in near and distance vision.

Main Results:

• The proposed drug combination demonstrated the ability to restore near vision in presbyopic individuals.
• Distance vision remained unaffected by the treatment.
• The specific pharmaceutical formulation used was found to be free of inflammatory or other adverse effects.

Conclusions:

• Pharmacological intervention using a combination of cholinergic agents and NSAIDs offers a potential solution for presbyopia.
• This treatment approach may effectively restore accommodative function, improving near vision without compromising distance acuity.
• The development of a safe and effective pharmaceutical form is crucial for clinical application.